David Karp's most recent trade in Northrim Bancorp, Inc. was a trade of 472 Common Stock done . Disclosure was reported to the exchange on Dec. 31, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Northrim Bancorp, Inc. | David W. Karp | Director | Other type of transaction at price $ 0.00 per share. | 31 Dec 2024 | 472 | 11,158 (0%) | 0% | 0 | Common Stock | |
| Northrim Bancorp, Inc. | David W. Karp | Director | Purchase of securities on an exchange or from another person at price $ 37.77 per share. | 02 May 2023 | 500 | 10,686 (0%) | 0% | 37.8 | 18,885 | Common Stock |
| Lumos Pharma Inc | David B. Karpf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | David B. Karpf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 3.52 per share. | 01 Feb 2023 | 1,000 | 8,330 (0%) | 0% | 3.5 | 3,520 | Common Stock |
| Lumos Pharma Inc | David B. Karpf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.53 per share. | 01 Feb 2023 | 36 | 8,294 (0%) | 0% | 3.5 | 127 | Common Stock |
| Northrim Bancorp, Inc. | David W. Karp | Director | Purchase of securities on an exchange or from another person at price $ 53.57 per share. | 16 Nov 2022 | 500 | 10,186 (0%) | 0% | 53.6 | 26,785 | Common Stock |
| Lumos Pharma Inc | David B. Karpf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.53 per share. | 01 Sep 2022 | 570 | 7,330 (0%) | 0% | 8.5 | 4,862 | Common Stock |
| Northrim Bancorp, Inc. | David W. Karp | Director | Purchase of securities on an exchange or from another person at price $ 41.03 per share. | 10 May 2022 | 2,000 | 9,686 (0%) | 0% | 41.0 | 82,060 | Common Stock |
| Northrim Bancorp, Inc. | David W. Karp | Director | Purchase of securities on an exchange or from another person at price $ 43.35 per share. | 28 Feb 2022 | 2,500 | 7,686 (0%) | 0% | 43.4 | 108,375 | Common Stock |
| Lumos Pharma Inc | David B. Karpf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | David B. Karpf | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 10.02 per share. | 01 Feb 2022 | 400 | 7,900 (0%) | 0% | 10.0 | 4,008 | Common Stock |
| Northrim Bancorp, Inc. | David W. Karp | Director | Purchase of securities on an exchange or from another person at price $ 44.68 per share. | 09 Jun 2021 | 550 | 5,186 (0%) | 0% | 44.7 | 24,574 | Common Stock |
| Northrim Bancorp, Inc. | David W. Karp | Director | Purchase of securities on an exchange or from another person at price $ 36.78 per share. | 26 Feb 2021 | 500 | 4,636 (0%) | 0% | 36.8 | 18,390 | Common Stock |